Table 4.

Distribution of GPX1 Pro198Leu polymorphism according to clinical stage and tumor grade

Cases	n	Genotype		p a	Allele		p
		Pro/Pro % [95% CI]	Pro/Leu % [95% CI]		Pro % [95% CI]	Leu % [95% CI]
Clinical stage
II	13	38.5 [29.55–48.3]	61.5 [51.7–70.45]	.020	69.2 [59.56–77.42]	30.8 [22.58–40.44]	.143
III	26	53.9 [44.17–63.34]	46.1 [36.66–55.83]		76.9 [67.68–84.13]	23.1 [15.87–32.32]
Tumor grade
I	2	100 [95.56–100]	0 [0.0–4.441]	NAa	100 [95.56–100]	0 [0.0–4.441]	NAa
II	4	25 [17.5–34.35]	75 [65.65–82.5]		62.5 [52.7–71.37]	37.5 [28.63–47.3]
III	34	50 [40.38–59.62]	50 [40.38–59.62]		75 [65.65–82.5]	25 [17.5–34.35]

rs1050450 C>T (NM_001329455.1).

CI, confidence intervals; n, number; NA, not applied.

Because of the limited number of cases with tumor grade I, statistical analysis couldn't be performed.

^aNo case has the Leu/Leu genotype; therefore this genotype was not included in the statistical analysis.